132 results about "Cell Maturation" patented technology

The present invention relates to a method of culturing peripheral lymphoid organ cells on a three-dimensional scaffolding which is covered or surrounded with culture medium, under conditions effective to generate and maintain mature and functional lymphoid cells, where the three-dimensional scaffolding allows cells in the culture medium to have cell to cell contact in three dimensions. The present invention also provides methods of screening for vaccine candidates for efficacy in eliciting an immune response, identifying genes or proteins which are related to peripheral lymphoid organ cell formation or function, screening for drugs effecting peripheral lymphoid organ cell maturation, treating a patient for a disease condition using antigen-specific lymphoid cells, and effecting gene expression of peripheral lymphoid organ cells.

The invention relates to a chimeric antigen receptor (CAR) and application thereof. The CAR comprises BCMA (B-cell maturation antigen) binding structural domains, transmembrane structural domains, oneor a plurality of co-simulation structural domains and intracellular signal transduction structural domains. The BCMA binding structural domains comprise heavy chain complementary determining regionsHCDR 1-3, and amino acid sequences of the HCDR 1-3 are sequentially shown as SEQ ID NO:1-3.

Provided are chimeric antigen receptors (CARs) having antigen specificity for B-cell Maturation Antigen (BCMA). Also provided are related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions relating to the CARs. Methods of treating or preventing cancer in a mammal are also provided.

The present invention relates to chimeric antigen receptor targeting BCMA(J22.9), and uses thereof, and particularly provides a polynucleotide sequence, which is selected from (1) a polynucleotide sequence containing the coding sequence of an anti-BCMA single chain antibody, the coding sequence of a human CD8 alpha hinge region, the coding sequence of a human CD8 transmembrane region, and the coding sequence of a human 41BB intracellular region, wherein the coding sequences are sequentially linked, and (2) a sequence complementary to the polynucleotide sequence (1). The present invention further provides a related fusion protein, a vector containing the coding sequence, and uses of the fusion protein, the coding sequences, and the vector.

B-cell maturation antigen (BCMA) is expressed on malignant plasma cells. The present invention provides BCMA-specific chimeric antigen receptors and cells expressing such chimeric antigen receptors. In certain embodiments, engineered cells expressing the chimeric antigen receptors of the present invention are capable of inhibiting the growth of tumors expressing BCMA. The engineered cells of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced BCMA-targeted immune response is desired and/or therapeutically beneficial. For example, engineered cells expressing the BCMA-specific chimeric antigen receptors of the invention are useful for the treatment of various cancers, including multiple myeloma.

Polypeptides and proteins that specifically bind to and immunologically recognize B-Cell Maturation Antigen (BCMA) are disclosed. Chimeric antigen receptors (CARs), anti-BCMA binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are also disclosed. Methods of detecting the presence of cancer and methods of treating or preventing cancer are also disclosed.

Human induced pluripotent stem cell (iPSC) technology combined with a hollow fiber based bioartificial liver (BAL) device can benefit patients with liver failure. Defined iPSC lines can provide unlimited supply of functional hepatocytes by developing iPSC derived hepatocytes (iHeps). Disclosed herein is a protocol for deriving metabolically active hepatocytes from iPSCs. In some embodiments, iHeps were cultured on microcarrier beads in spinner flasks. Subsequently, the iHep-microcarrier complexes were loaded into the extracapillary space of a hollow fiber bioreactor cartridge and cultured using closed circuit continuous flow system. The iHeps secreted human albumin, prothrombin and apolipoprotein B into the hollow fiber intracapillary space media which indicated the maintenance of plasma protein secretory function. In addition, the continuous flow system improved the maturation of iHeps. Thus, the iPSC hepatocytes in the bioartificial liver device maintained the secretory function and exhibited cell maturation.

The invention belongs to the technical field of genetic engineering, and specifically relates to an anti-BCMA (B-cell Maturation Antigen) humanized single-chain antibody and application thereof. The amino acid sequence of the anti-BCMA humanized single-chain antibody is as show in SEQ ID NO: 19 or 20 or 21 or 22 or 23. The anti-BCMA humanized single-chain antibody is formed by sequentially connecting a light chain variable region, a Linker and a heavy chain variable region; the humanization degree is high; the immunogenicity of CAR (Chimeric Antigen Receptor) can be effectively reduced; the continuity and safety of CAR-T (Chimeric Antigen Receptor T-cell) in vivo can be enhanced.

The invention discloses a human immunocompetent cell DC-CIK cell preparation and an effective preparation method of the human immunocompetent cell DC-CIK cell preparation. The method includes the following steps: (1) isolating single mononuclear cell from the human peripheral blood; (2) inoculating the single mononuclear cell into the serum-free medium, adding IFN gamma, GM-CSF and IL-4 and culturing for 1 day; (3) adding IL-2, IL-15 and anti-CD3 monoclonal antibody and culturing for 2 days; (4) adding TNF alpha, continuously culturing for 1day and promoting the DC cell maturation; (5) adding IL-2 and IL-15, continuously culturing for 8 days and obtaining the DC-CIK cell; and (6) collecting the DC-CIK cell and preparing the cell preparation. Through the culturing program of the DC-CIK cell, the human immunocompetent cell DC-CIK cell preparation not only can shorten the cell culturing time, improve the multiplication rate and strengthen the killing activity of the DC-CIK cell on the cancer cell, but also can simplify the operating steps and facilitate the clinic popularization and application.

The invention provides mannose phosphate and salts thereof for increasing vaginal cell growth, vaginal cell maturation and vaginal moisture, as well as compositions, articles and methods for treating and preventing vaginal conditions characterized by poor vaginal cell growth, low vaginal cell differentiation and low vaginal moisture.

The invention provides a vaccine for treating mRNA-DC lung cancer and an enhanced preparation method of the vaccine. The method includes the steps of obtaining mRNA, IL-2 and IFN-gamma of a lung cancer stem cell, and transfecting the mRNA, the IL-2 and the IFN-gamma into DC to be cultivated in vitro. According to the method process, based on the technological foundation that the DC can receive and translate the external mRNA and codon has universality, the DC is stimulated through the method that antigen proteins are expressed after the mRNA of the lung cancer stem cell is guided in and replace inactivated proteins for stimulation, and the carried antigen information is more comprehensive; the defect that due to inactivation, breakage and the like of the externally-stimulated antigen proteins, the antigen information is lost can be overcome; meanwhile, the IL-2 and the IFN-gamma are transfected into the DC, then the mature induction can be started in the immune response process, the induction time in an ordinary culture medium can be greatly shortened, the cell maturation efficiency is improved, and immune responses are enhanced. The invention further provides a cytotoxic T lymphocyte obtained by co-culturing the vaccine for treating mRNA-DC lung cancer and a T lymphocyte.